ReviewPharmacotherapy2008
Warfarin pharmacogenetics.
Review in Pharmacotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 125 citations in OpenAlex.
- Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.Heart (British Cardiac Society) · 2017Trial
- Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses.Clinical medicine & research · 2011Trial
- Bridging genomics' greatest challenge: The diversity gap.Cell genomics · 2025Review
- A Case of Unexplained Warfarin Resistance: A Case Report and Literature Review.The journal of Tehran Heart Center · 2023Article
- Association of Genetic Polymorphisms with Complications of Implanted LVAD Devices in Patients with Congestive Heart Failure: A Kazakhstani Study.Journal of personalized medicine · 2022Article
- Premarket assessment of molecular alterations in drug targets: a case study of 2020 drug approvals.Pharmacogenomics · 2022Article
- Functional Assessment of 12 Rare AllelicJournal of personalized medicine · 2021Article
- Article
- Verification of pharmacogenomics-based algorithms to predict warfarin maintenance dose using registered data of Japanese patients.European journal of clinical pharmacology · 2019Article
- Relationship between warfarin dosage and international normalized ratio: a dose-response analysis and evaluation based on multicenter data.European journal of clinical pharmacology · 2019Article
- Racial, Ethnic, and Socioeconomic Inequities in the Prescription of Direct Oral Anticoagulants in Patients With Venous Thromboembolism in the United States.Circulation. Cardiovascular quality and outcomes · 2019Article
- Plasma Response to Deuterium-Labeled Vitamin K Intake Varies by TG Response, but Not Age or Vitamin K Status, in Older and Younger Adults.The Journal of nutrition · 2019Article
- The pharmacoepigenomics informatics pipeline defines a pathway of novel and known warfarin pharmacogenomics variants.Pharmacogenomics · 2018Article
- Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application.International journal of biomedical investigation · 2018Article
- Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients.Pharmacogenomics and personalized medicine · 2018Article
- A New Approach towards Minimizing the Risk of Misdosing Warfarin Initiation Doses.Computational and mathematical methods in medicine · 2018Article
- Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients.British journal of clinical pharmacology · 2017Article
- Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting.The American journal of medicine · 2017Article
- Hematoma Expansion Following Intracerebral Hemorrhage: Mechanisms Targeting the Coagulation Cascade and Platelet Activation.Current drug targets · 2017Review
- Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review.Iranian journal of pharmaceutical research : IJPR · 2016Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Significant interest in the pharmacogenetics of warfarin therapy has been triggered with the recent package insert update that highlights the potential role of pharmacogenetics in improving the safety and effectiveness of warfarin. We review the evidence of the influence of the two key genes of interest, the cytochrome P450 2C9 gene, CYP2C9, and the vitamin K epoxide reductase complex 1 gene, VKORC1, on warfarin response and discuss the implications of current knowledge for clinical practice. The influence of CYP2C9 and VKORC1 genotypes on warfarin dose requirements has been consistently demonstrated in diverse racial and ethnic patient groups in observational studies and randomized clinical trials. Dosing algorithms have been developed that incorporate clinical, demographic, and genetic information to help select a warfarin starting dose. Furthermore, CYP2C9 variant genotypes have been associated with a significantly increased risk of serious bleeding events. However, evidence to date from prospective, controlled studies has not demonstrated an added benefit of incorporating genotype-guided therapy in improving anticoagulation control or in preventing or reducing the risk of hemorrhagic or thromboembolic complications. Research efforts designed to evaluate the effectiveness of genotype-guided therapy in improving outcomes are under way. However, the routine use of CYP2C9 and VKORC1 genotyping in the general patient population who begin warfarin therapy is not supported by evidence currently available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.